Granules India Applies For First-To-File Status On Generic Cancer Drug Ruxolitinib

Drugmaker Granules India has filed a Paragraph IV certification with the U.S. Food and Drug Administration for its abbreviated new drug application covering Ruxolitinib Extended-Release Tablets. Granules stated that it believes it qualifies for first-to-file status based on the timing and status of this application, subject to a review and determination by the U.S. regulatory body.

Exclusivity And Patents

If the FDA confirms this status, Granules could become eligible for 180 days of generic drug exclusivity under American law. The company announced this update on Wednesday, September 7, 2026, noting that the certification addresses applicable patents listed in the FDA's Orange Book and that it has given the required notices to relevant parties.

Company Strategy

Granules CMD Krishna Prasad Chigurupati stated that first-to-file opportunities form a key part of the company's plan to build a more varied and higher-value product portfolio. He added that the filing shows the firm's focus on finding attractive commercial and technical opportunities where its manufacturing skills create lasting value. Ruxolitinib is a JAK1 and JAK2 inhibitor that received FDA approval in 2011 to treat specific cancers and related conditions.

Market Presence

In the American market, the drug is developed and marketed by Incyte Corporation under the brand name Jakafi, with Jakafi and Jakafi XR serving as Incyte trademarks. Incyte reported in May that the FDA approved Jakafi XR as the extended-release version of the medication. Outside the U.S., the drug is sold by Novartis under the brand name Jakavi.

Context

Drug companies often seek first-to-file status to gain a valuable period of market exclusivity without direct generic competition. This process involves challenging existing patents listed by brand-name drug manufacturers in regulatory Orange Books. Understanding these filings helps explain how generic medicine markets operate and how companies attempt to launch affordable alternatives.